However, with a dramatic toxicity event difference shown in data analysis, the result favored BRAF inhibition over combination treatment in dermatologic diseases, including alopecia (RR = 0.31; 95% CI, 0.27, 0.36; P < 0.00001), arthralgia (RR = 0.65; 95% CI, 0.59, 0.71; P < 0.00001), hyperkeratosis (RR = 0.31; 95% CI, 0.26, 0.37; P < 0.00001), and cutaneous squamous‐cell carcinoma (RR = 0.21; 95% CI, 0.14, 0.30; P < 0.00001). The gene discussed is BRAF; the disease is Hyperkeratosis.